Literature DB >> 10675491

Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).

B Aunoble1, R Sanches, E Didier, Y J Bignon.   

Abstract

Ovarian cancer remains the leading cause of death from gynecologic malignancy in Western countries. This cancer results from a succession of genetic alterations involving oncogenes and tumor suppressor genes which have a critical role in normal cell growth regulation. Mutations and/or overexpression of three oncogenes, HER-2/neu, c-myc and K-ras, and of the tumor suppressor gene p53, have frequently been observed in sporadic ovarian cancer. In the context of high risk families, the most frequently involved genes are BRCA1 and BRCA2. We review the function of these different proteins, the incidence of mutations in their genes in carcinogenesis and as potential prognostic factors in sporadic and hereditary ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675491     DOI: 10.3892/ijo.16.3.567

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  49 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.

Authors:  Vladimir Tolmachev; Heng Xu; Helena Wållberg; Sara Ahlgren; Magnus Hjertman; Anna Sjöberg; Mattias Sandström; Lars Abrahmsén; Martin W Brechbiel; Anna Orlova
Journal:  Bioconjug Chem       Date:  2008-07-12       Impact factor: 4.774

3.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

Authors:  J B Welsh; P P Zarrinkar; L M Sapinoso; S G Kern; C A Behling; B J Monk; D J Lockhart; R A Burger; G M Hampton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

4.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Authors:  Selene Nunez-Cruz; Phyllis A Gimotty; Matthew W Guerra; Denise C Connolly; You-Qiang Wu; Robert A DeAngelis; John D Lambris; George Coukos; Nathalie Scholler
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

5.  Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis.

Authors:  Karen L Abbott; Jae-Min Lim; Lance Wells; Benedict B Benigno; John F McDonald; Michael Pierce
Journal:  Proteomics       Date:  2010-02       Impact factor: 3.984

6.  Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.

Authors:  Federica Barbieri; Adriana Bajetto; Tullio Florio
Journal:  J Oncol       Date:  2009-12-14       Impact factor: 4.375

7.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

8.  Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.

Authors:  Sharon J Pitteri; Lellean JeBailey; Vitor M Faça; Jason D Thorpe; Melissa A Silva; Reneé C Ireton; Marc B Horton; Hong Wang; Liese C Pruitt; Qing Zhang; Kuang H Cheng; Nicole Urban; Samir M Hanash; Daniela M Dinulescu
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

9.  Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.

Authors:  Katherine V Clark-Knowles; Mary K Senterman; Olga Collins; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  Ovarian cancer mouse models: a summary of current models and their limitations.

Authors:  Miranda Y Fong; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-09-28       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.